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Abstract
Background: The NAA10-NAA15 (NatA) protein complex is an N-terminal acetyltransferase responsible for
acetylating ~ 40% of eukaryotic proteins. In recent years, NAA10 variants have been found in patients with an
X-linked developmental disorder called Ogden syndrome in its most severe form and, in other familial or de novo
cases, with variable degrees of syndromic intellectual disability (ID) affecting both sexes.
Case presentation: Here we report and functionally characterize a novel and de novo NAA10 (NM_003491.3) c.332 T >
G p.(V111G) missense variant, that was detected by trio-based whole exome sequencing in an 11 year old girl with mild/
moderate non-syndromic intellectual disability. She had delayed motor and language development, but normal behavior
without autistic traits. Her blood leukocyte X-inactivation pattern was within normal range (80/20). Functional
characterization of NAA10-V111G by cycloheximide chase experiments suggests that NAA10-V111G has a reduced
stability compared to NAA10-WT, and in vitro acetylation assays revealed a reduced enzymatic activity of monomeric
NAA10-V111G but not for NAA10-V111G in complex with NAA15 (NatA enzymatic activity).
Conclusions: We show that NAA10-V111G has a reduced stability and monomeric catalytic activity, while NatA function
remains unaltered. This is the first example of isolated NAA10 dysfunction in a case of ID, suggesting that the syndromic
cases may also require a degree of compromised NatA function.
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Background
The NAA10-NAA15 protein complex (NatA) is an
N-terminal acetyltransferase (NAT) responsible for
acetylating (Nt-acetylating) ~ 40% of eukaryotic proteins
[1, 2]. NAA10 is the catalytic subunit that NAA15 is
docking to the ribosome, forming a catalytically active
complex (the NatA complex) that acetylates N-termini
of newly synthesized peptide chains as the chain
emerges from the ribosomal exit tunnel [3–7]. The NatA
complex will acetylate peptide chains with either serine,
alanine, glycine, threonine, valine or cysteine as the
N-terminal residue after the initiator methionine has
been cleaved off by Methionine aminopeptidases [1, 8].
In addition to its role in NatA mediated cotranslational
acetylation and propionylation [9], monomeric NAA10
is believed to have NatA independent roles, e.g.
post-translational Nt-acetylation of proteins with neo-N-
termini [10], acetylation of lysine side chains (K-acetyl-
ation) [11–13] and acetyltransferase independent roles
such as protein-protein interactions with for instance
DNA methyltransferase 1 (DNMT1) or p21-activated
kinase-interacting exchange factor (PIX) [14–16].
NAA10 is an essential gene in Trypanosoma brucei, Cae-
norhabditis elegans and Drosophila melanogaster and
essential for normal development in Danio rerio [17–20].
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In the years since the human NatA complex was iden-
tified and characterized, both NAA10 and NAA15 have
repeatedly been associated with different types of cancer,
suggesting a role in regulating cell proliferation and sur-
vival [21]. In recent years several different NAA10 vari-
ants have been linked to rare genetic disorders. In 2011,
a NAA10 c.109 T > C p.(S37P) missense variant was
identified as the cause of the X-linked Ogden syndrome
(the locus for NAA10 is Xq28) [22–24]. The patients
affected by Ogden syndrome were all boys from two
independent families (5 in one, 3 in the other). Ogden
syndrome is associated with severe developmental delay
(DD), a lipodystrophic facial appearance, short stature,
microcephaly, cardiac arrhythmias and multiple malfor-
mations. All of the boys died before 2 years of age.
Carrier females of the Ogden syndrome NAA10 variant
all have skewed (> 90%) X-inactivation patterns and have
no reported phenotypes [23]. Casey and colleagues
described a second NAA10 missense variant, c.128A > C,
p.(Y43S), in two adult male patients with syndromic in-
tellectual disability (ID), cardiac dysfunction (long-QT
interval) and scoliosis, but not Ogden syndrome [25].
The variant was de novo in their mildly affected mother;
a female with learning problems and heart disease (long-
QT interval and ventricular tachycardia). Her blood
leukocyte X-inactivation pattern was balanced.
In addition to the two missense variants described
above, several NAA10 variants that also affect females
have been identified. Esmailpour and colleagues identi-
fied a 2 bp splice donor site deletion (c.471 + 2 T > A) in
three brothers and an uncle with Lenz micropthalmia
syndrome [26], a condition with ID, dysmorphic features
and other malformations. Heterozygous carrier females
may have mild manifestations [26]. Another NAA10
variant, c.346C > T p.(R116W) was identified both in a
female and a male, the latter being more severely affected
[27]. In addition four NAA10 missense variants c.319G >T
p.(V107F), c.247C >T p.(R83C), c.382 T >A p.(F128I) and
c.384 T >A p.(F128 L) have been found in female patients
with moderate, severe or profound ID, postnatal growth
failure, as well as skeletal and cardiac anomalies [27, 28].
Here we describe an 11 year old female with mild/
moderate non-syndromic ID. Whole exome sequencing
(WES) revealed de novo occurrence of a previously
undescribed NAA10 missense variant c.332 T > G
p.(V111G). Functional testing demonstrated a decreased
stability of overexpressed NAA10-V111G, decreased
monomeric NAA10-V111G catalytic activity, while the
NatA catalytic activity remained unchanged.
Case presentation
Patient description
The patient is a girl, now 11 years old, born three weeks
preterm by section due to transverse lie, birth weight
2720 g. There were no feeding difficulties in infancy or
later. Motor and language development was delayed: she
walked without support at age 2½ years, and at age
3 years she said her first words. At age 10 years she
knew the alphabet and tried to put letters together. She
used diapers until age 8–9 years. Her sleep pattern is
mildly irregular with frequent awakenings. Congenital
malformations or epilepsy have never been detected. She
has normal stature with length along the 25th–50th
centile and weight along the 25th centile, but her head
circumference has been in the lower normal range (2.5th
- 5th centile). Her facial features are also normal - she is
not clearly dysmorphic. Behavior is normal without
autistic traits, but bruxism is a problem. She prefers the
company of younger children. Her intellectual level is
judged to be comparable to mild-moderate ID, formal
IQ testing has not yet been done. At age 9 years trio
whole exome sequencing (WES), comparing child to
parental DNA sequences, revealed a de novo NAA10
(NM_003491.3) c.332 T > G p.V111G variant which was
further confirmed by Sanger sequencing.
NatA homology model, prediction tools, structural
conservation.
In line with other NAA10 missense variants, the V111G
substitution affects a highly conserved amino acid (Fig. 1,
panels A and B). NAA10 is a 235 amino acid protein
which adapts the characteristic GNAT fold common to
NAT catalytic subunits. This fold consists of six or seven
β strands and four α helices (Fig. 1c). β-strands 2-5
constitute the core of the protein. These four β strands,
together with the α2 helix and the β6-β7 loop important
for substrate binding, are highly conserved. V111 is
located towards the end of the β5 strand, and a valine in
this position is highly conserved in NAA10 homologues
as well as in several other NAT catalytic subunits for
which crystal structures have been solved (Fig. 1c, data
not shown (PDB ID: 5K04 (NAA20), 4U9W (NAA40),
3FTY (NAA50), 5ICV (NAA60) and 4LX9 (ssNAT))
[29–33]. The side chain of V111 is forming a hydropho-
bic pocket together with Y145, M147, L119 and L109. It
is also in close proximity (3.7 Å) to the sulphur group of
Acetyl-CoA (AcCoA), which could indicate a role for
V111 in positioning of AcCoA (Fig. 1d). A glycine in this
position will not cause any steric clashes, but loss of the
more bulky hydrophobic side chain of valine may
possibly cause structural alterations affecting protein sta-
bility or AcCoA binding.
Functional testing
In order to functionally assess NAA10-V111G, we first
expressed His/MBP-NAA10-WT and His/MBP-NAA10-
V111G in E.coli, purified enzymes and tested the in vitro
NAT activity. Contrary to His/MBP-NAA10-WT, it was
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difficult to obtain good protein expression of His/MBP-
NAA10-V111G, and a substantial fraction of the purified
His/MBP-NAA10-V111G molecules eluted in the void
volume of the size exclusion chromatography column
(Fig. 2, panels A and B). This indicate that parts of the
protein aggregate in units larger than 200 kDa, most
likely due to an alteration of the protein structure, or
reduced protein stability. Enzymes that eluted at a col-
umn volume corresponding to monomeric His/MBP-
NAA10-V111G were tested for catalytic activity and
shown to have an approximately 85% reduction in
catalytic activity compared to His/MBP-NAA10-WT
(Fig. 2, panels C and D).
Due to the low expression levels and protein yield of
NAA10-V111G from E.coli transfection and protein
purification, we transfected HeLa cells with plasmids
coding for either V5-tagged NAA10-WT or V5-tagged
NAA10-V111G followed by immunoprecipitation (IP) of
the overexpressed protein by an anti-V5 antibody.
Thereafter, NAT activity in the precipitate was measured
(Fig. 3). NAA10 and NAA15 form a high-affinity protein
complex (Fig. 1e), and as expected endogenous NAA15
Fig. 1 NAA10 multiple sequence alignment and structural conservation. a NAA10 multiple sequence alignment showing amino acids 78–137 (of
human NAA10) (b) Previously described NAA10 variants identified in patients with ID/DD. c Cartoon representation of NAA10 colored with respect to
evolutionary conservation. More conserved regions are colored in dark magenta, less conserved regions are colored in dark cyan. V111 is located
towards the end of β5 and is highly conserved throughout evolution. d The side chain of V111 is pointing towards a hydrophobic pocket together
with Y145, M147, L109 and L119. V111 is also located in close proximity to the sulfur-acetyl group of AcCoA, and to the β6-β7 loop region that is very
important for peptide substrate binding. e Homology model of the human NatA complex. The auxiliary subunit NAA15 is shown in yellow cartoon,
the catalytic subunit NAA10 is shown in white cartoon and the AcCoA is shown as green sticks
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co-immunoprecipitated with both overexpressed
NAA10-WT-V5 and NAA10-V111G-V5. The amount of
NAA10 and NAA15 present in each sample were deter-
mined by SDS-PAGE and Western blotting. Bands from
the Western blot were quantified, and the measured
catalytic activity was correlated with the amount of
NAA10-V5 present in the sample (i.e. a mixture of
monomeric NAA10 and NAA10 in complex with
NAA15 – the NatA complex), and separately correlated
with the amount of NAA15 present in the sample (i.e.
the amount of the NatA complex only). Results from the
IP-activity experiment corresponded well with our previ-
ous finding (Fig. 2): the ability of NAA10-V111G to
acetylate the acidic N-termini EEEI24 was greatly
reduced (Fig. 3, panels B and C). However, it also
revealed a second interesting feature: As can be seen
from the Western blot in Fig. 3a, more NAA15 co-
immunoprecipitated with NAA10-V111G-V5 compared
to NAA10-WT-V5. This was also reflected in our NAT-
activity measurements where the immunoprecipitated
NAA10-V111G-V5 sample showed higher NatA product
formation (for the NatA substrate polypeptide SESS24)
compared to the immunoprecipitated NAA10-WT-V5
sample when correlating for the amount of total
NAA10-V5 present in the sample (Fig. 3b). However,
when correlating for the amount of NAA15 present in
each sample, the NatA product formation per NAA15
molecule (and thus NatA complex) was approximately
equal (Fig. 3c). As monomeric NAA10 has a 1000-fold
lower NAT-activity towards NatA substrates compared
to the NatA complex [10], the contribution of mono-
meric NAA10 on acetylation of SESS24 is minimal.
Taken together, this suggest that NAA10-V111G has
reduced catalytic activity in a monomeric form, but not
in complex with NAA15.
NAA10-WT and NAA10-V111G protein turnover
In order to assess protein turnover of NAA10-WT and
NAA10-V111G, we expressed V5-tagged NAA10-WT
and NAA10-V111G in HeLa cells and performed
cycloheximide-chase experiments. As can be seen from
Fig. 4, NAA10-V111G-V5 has a higher turnover rate
than NAA10-WT-V5. 2 h after cycloheximide treatment,
the average amount of NAA10-V111G-V5 was reduced
by approximately 80%, while NAA10-WT-V5 molecules
was reduced by 20% relative to the amount of NAA10
molecules before cycloheximide treatment. Although the
amount of NAA10-V111G-V5 is drastically decreased
Fig. 2 Protein purification and in vitro N-terminal acetyltransferase assays (a). Size exclusion chromatography of His/MBP-NAA10-V111G and His/
MBP-NAA10-WT. Both the void volume (peak 1), and the monomeric peak at approximately 74 ml (peak 2) contain His/MBP-NAA10-WT or His/
MBP-NAA10-V111G. The peaks corresponding to monomeric NAA10 (approximately at 75 mL) was further used for enzymatic experiments. b All
fractions were analyzed by SDS-PAGE. c Time dependent Nt-acetylation of the substrate peptide EEEI24 catalyzed by His/MBP-NAA10-WT and His/
MBP-NAA10-V111G. d Nt-acetylation of substrate peptides EEEI24 and DDDI24 catalyzed by His/MBP-NAA10-WT and His/MBP-NAA10-V111G.
* statistically significant (p < 0.0001, student t-test)
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after 2 h, the level of NAA10-V111G-V5 seems to
stabilize at around 20%. Most likely overexpressed
NAA10-V111G-V5 is present both in an unstable mono-
meric form that is rapidly degraded and in complex with




Whole exome sequencing was performed on trios on
genomic DNA isolated from blood. DNA samples were
prepared using the SeqCap EZ MedExome Kit (Roche,
Bazel, Switzerland) and followed by paired-end 150 nt
sequencing on the Illumina NextSeq500. Alignment and
variant calling was performed as previously described
[34]. Average median coverage of the target region was
207X with 100% of target region covered with at least
20 reads. Data annotation and interpretation were
performed using the Cartagenia Bench Lab, NGS
module (Cartagenia, Leuven, Belgium). The NAA10
variant was verified by targeted Sanger sequencing.
Informed consent was obtained from patient index
and family members.
Multiple sequence alignment, conservation scores and
homology model.
Multiple sequence alignments were created using
ClustalX [35] and the illustration using ESPript3.0
[36]. Conservation scores, and coloring schemes for
the NAA10 model shown in Fig. 1b was made using
ConSurf [37–40]. The human NatA homology model
was created and published previously [23].
Preparation of plasmids
In order to study the NM_003491.3 c.332 T > G
(p.V111G) missense variant a bacterial expression vector
pETM-41/His-MBP-NAA10 and mammalian expression
vector pcDNA3.1/NAA10-V5-His were modified by site-
directed mutagenesis (Q5® Site Directed Mutagenesis
Kit, New England Biolabs) according to the manufac-
turer’s protocol.
Fig. 3 NAT-activity of immunoprecipitated NAA10-WT-V5 and
NAA10-V111G-V5. a Western blot of immunoprecipitated NAA10-
WT-V5 and NAA10-V111G-V5 using anti-V5. b Catalytic activity of
immunoprecipitated NAA10-WT-V5 and NAA10-V111G-V5 correlated
towards the amount of NAA10-V5 present in each sample. c Catalytic
activity of immunoprecipitated NAA10-WT-V5 and NAA10-V111G-V5
correlated towards the amount of NAA15 present in each sample. NAT
activity experiments were performed in triplicates. * statistically significant
(p< 0.0001, student t-test). The data presented are representative for
three independent experiments
Fig. 4 Cycloheximide chase experiments. a Western blot showing
the protein levels of overexpressed NAA10-WT-V5 and NAA10-
V111G-V5 before and 2, 4 and 6 h after protein synthesis was
stopped by the addition of cycloheximide. b Quantification of
NAA10-V5 bands from cycloheximide chase experiments. Western
blots from 6 independent experiments were quantified using Imagelab
3.0 from Biorad, and the intensities in each band 2, 4 and 6 h after
cycloheximide treatment were correlated both to the loading control
(anti-β-tubulin) and to the intensity in the band representing NAA10-
V5 before cycloheximide treatment. Each curve represents the average
levels of NAA10 from 6 independent experiments combined. * statistically
significant (p< 0.0005, student t-test)
McTiernan et al. BMC Medical Genetics  (2018) 19:47 Page 5 of 9
Protein expression in E.coli BL21 cells
In order to study the in vitro catalytic activity of the
novel NAA10 variant, recombinant His/MBP-NAA10-
WT and His/MBP-NAA10-V111G were expressed in
BL21 Star™ DE3 competent E. coli cells for protein puri-
fication. Cells were grown to an OD600 of 0.6 and pro-
tein expression was induced by adding 0.5 mM IPTG to
the LB-media. The culture was incubated overnight at
18 °C to allow sufficient expression of His/MBP-NAA10.
The following morning, the culture was centrifuged at
4750 rpm for 20 min to harvest cells and cell pellets
were stored at − 20 °C until use. A two-step purification
protocol (affinity chromatography and size exclusion
chromatography was performed as described [28]) and
the purified protein was analysed by SDS-PAGE and
coomassie.
In vitro acetylation assays
In vitro DTNB-based acetylation assays were performed
to study the catalytic activity of the purified His/MBP-
NAA10 variants as described [27]. In short, acetylation
assays were performed simultaneously for both His/
MBP-NAA10 WT and His/MBP-NAA10 V111G in
order to compare their catalytic activity. 500 μM sub-
strate polypeptide, 500 μM acetyl-CoA, 1× Ac buffer,
ddH20 and enzyme were mixed to a final volume of
50 μl. In addition, two negative replicates without en-
zyme were prepared. Samples were incubated at 37 °C
on a heating block and the reaction was quenched at dif-
ferent time points by adding 100 μl Quenching buffer
(3.2 M guanidine-HCl, 100 mM Na2HPO4 pH 6.8).
Samples were then mixed with 20 μl of DTNB buffer
(100 mM Na2HPO4, 10 mM EDTA pH 6.8) saturated
with DTNB, and the absorbance was measured at
412 nm using an Epoch microplate reader.
Immunoprecipitation of NAA10-WT-V5 and NAA10-
V111G-V5
For each IP experiment, five 10 cm dishes of HeLa cells
(ATCC, CCL-2) were transfected with 4 μg NAA10
WT-V5 and eight dishes were transfected with 10 μg of
each NAA10-V111G-V5. 6 μg of empty V5-vector was
co-transfected with NAA10-WT-V5 to ensure equal
conditions for the cells. 48 h post transfection, cells were
harvested using a cell scraper, and centrifuged at 1500 x
g for 5 min. The resulting cell pellet was washed in 5 ml
1× PBS, centrifuged again and lysed in 350 μl IPH buffer
containing 1× protease inhibitor per cell dish on ice for
30 min. The lysed cells were then centrifuged at 17000 x
g for 1 min to remove cell debris and the supernatant
was transferred to a new tube. 30 μl cell lysate was saved
for Western blot analysis.
Cell lysates were incubated with 5 μg anti-V5 on a
rotating wheel at 4 °C for 2–3 h to allow formation of
immune complexes. 60 μl washed magnetic beads were
then added to each IP sample and incubated at 4 °C on
a rotating wheel overnight to retrieve the immune com-
plexes. The next day, the IP samples were placed on a
magnetic holder and 30 μl of the supernatant was saved
for western blot analysis. The IP beads were washed 3×
in 1 ml IPH buffer and 2× in acetylation buffer. Finally
the washed IP beads were resuspended in 95 μl acetyl-
ation buffer and were ready to be used in C14 acetyl-
ation assays.
Carbon-14 acetylation assay
C14 acetylation assays were performed to assess the
intrinsic NatA activity of the immunoprecipitated NatA
complexes. Acetylation assays were performed simultan-
eously for mutant and WT IP samples in order to com-
pare their catalytic activity. Three positive replicates of
200 μM specific peptide (SESS24 or EEEI24), 100 μM
unlabeled AcCoA, 100 μM 14C-labelled AcCoA, 10 μl
IP beads and dH2O were mixed to a final volume of
25 μl. In addition, two negative replicates without
peptide were prepared. The samples were incubated at
37 °C and 1300 rpm on a thermo shaker for 35 min.
After incubation, the samples were placed on a magnet
holder to isolate the magnetic beads and 23 μl sample
was transferred to P81 phosphocellulose discs. The
paper discs were then washed 3 × 5 min in 10 mM
HEPES buffer followed by air drying on paper. The dried
discs were placed in individual tubes, filled with 5 ml
scintillation fluid and the C14 signal was measured using
a scintillation counter. The IP samples were analyzed by
Western blotting (as briefly described above) and the
measured activity was adjusted to quantification of cor-
responding anti-V5 bands.
Cycloheximide chase experiments
HeLa cells were cultured in DMEM growth medium
(Sigma) supplemented with 10% fetal bovine serum
(FBS) and 3% L-Glutamine and incubated at 37 °C with
5% CO2. Cells were transfected at approximately
60–70% confluence, in the log-phase of growth, to
maximize the transfection efficiency. 3 × 4 wells of cells
in 6-well plates were prepared per NAA10 variant (WT
and V111G). Cells were transfected with 2.6 μg of V5-
vector encoding NAA10 WT or V111G using Xtreme-
GENE 9 DNA transfection reagent (Roche) according to
the manufacturer’s protocol and DMEM growth medium
was replaced 4–6 h post transfection. 48 h post transfec-
tion, the growth medium of each well was replaced with
2 ml medium containing 50 μg/ml Cycloheximide. Cells
were harvested using a cell scraper at 0 h, 2 h, 4 h and
6 h after the cycloheximide addition. The cells harvested
at time point 0 h were not treated with cycloheximide.
Harvested cells were centrifuged at 4 °C using the “short
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spin” function of a Heraeus Fresco 17 centrifuge for 15 s
with 17,000 g as the maximum speed and the cell pellets
were washed in 1 ml cold 1× PBS, centrifuged again and
stored at − 80 °C.
Western blot analysis
In order to analyse NAA10 turnover, cell samples were
analysed by Western blotting. Cell pellets were lysed by
resuspension in 30 μl IPH lysis buffer (50 mM Tris-HCl
pH 8.0, 150 mM NaCl, 5 mM EDTA and 0.5% NP-40,
1× complete EDTA free protease inhibitor) and incuba-
tion on ice for 20 min. Cell debris was removed by
centrifugation at 4 °C and 17,000 x g for 8 min and the
supernatant was analysed by SDS-PAGE and Western
blotting as described [25]. In order to visualize NAA10-
V5 and β-tubulin, a 1:3000 dilution of primary ab (anti-
V5, anti-tubulin) in 1% dry milk overnight at 4 °C with
gentle shaking was used followed by a 1:3000 dilution of
secondary ab anti-mouse or anti-rabbit (dependent on
the primary ab) diluted in 3% dry milk for 1 h at room
temperature with gentle shaking. HRP signals were
developed using SuperSignal® West Pico Chemilumines-
cent Substrate (Thermo Scientific) followed by detection,
imaging and quantification using ChemiDoc™ XRS+ con-
nected with ImageLab™ v3.0 (Bio-Rad).
Discussion and conclusions
In recent years the phenotypic spectrum associated with
NatA-deficiency has greatly expanded. Several NAA10
variants have been identified, some mainly affecting
males [22, 25] and some affecting both males and
females [27, 28]. Here we characterize a previously
undescribed NAA10 de novo missense change,
p.(V111G) in an 11 year old female with mild/moderate
ID. We show that NAA10-V111G has a reduced stability
and loss of catalytic activity in monomeric form, but
most likely remains active and stable when bound to
NAA15 in the NatA complex. V111 is positioned
towards the end of the β5 strand, with a hydrophobic
side chain contributing to a hydrophobic pocket in the
core of the protein. Substituting the more bulky hydro-
phobic side chain of valine with a hydrogen atom only
will cause loss of any hydrophobic contacts the valine
side chain took part in. In addition, the unique achirality
of glycine makes it able to adopt different Cα backbone
rotation angles than all other amino acids, possibly
increasing the flexibility in these bonds. Although V111
and the hydrophobic pockets surrounding V111 is not in
direct contact with NAA15 (Fig. 1e), our results indicate
that the increased flexibility and/or reduced stability
most likely is restored by NAA15 binding.
Several other NAA10 missense variants have previ-
ously been found to affect NAA10 protein stability
(NAA10-V107F [28], NAA10-Y43S [25], NAA10-F128I
and NAA10-F128L [27]). With the exception of Y43, all
of these residues are situated in one of the highly con-
served β-strands β4, β5 or β6 in the core of the protein.
The side chains of V107 and F128 (which were altered
in other patients with ID) form a hydrophobic pocket in
close proximity to the hydrophobic pocket surrounding
V111 [27]. It is therefore conceivable that V111G cause
disease through similar mechanisms as V107F, F128L
and F128I variants. The phenotypic spectrum of this
group of patients is very broad, ranging from learning
problems (in a mother heterozygous for Y43S) to severe
intellectual disability, heart disease (arrhythmias) and
short stature. Females can also have a severe phenotype
as illustrated by three females with de novo V107F,
F128I and F128L variants, respectively [27, 28]. In con-
trast, female carriers of the p.(S37P) variant causing
Ogden syndrome appear to be normal [23], probably
because the missense variant is severe enough to skew
X-inactivation at an early stage of development. Saunier
and colleagues described seven unrelated females shar-
ing the NAA10-R83C missense change. In five of them,
the blood leukocyte X-inactivation patterns were deter-
mined. It was normal (balanced) in three, and skewed
(92% and 100%) in two. The girl with 100% skewing was
the only NAA10-R83C individual without microcephaly
or postnatal growth retardation [27]. X-inactivation pat-
terns were also tested in four of the female patients with
NAA10 variants affecting the same hydrophobic pocket
as V111 [27, 28]. All had random X-inactivation
patterns, in line with lack of phenotype rescue by
early deselection of cells expressing the NAA10
variants. Our patient had an X-inactivation pattern of
80/20, phase unknown, which is within our defined
normal range of 15–85%.
Although a lot is known about NAA10 function when
in complex with NAA15, the functions of monomeric
NAA10 remain disputed. Although an in vivo NAT-
substrate for monomeric NAA10 is yet to be found, it has
a strong substrate preference for acidic N-termini in vitro
and should be capable of catalyzing post-translational Nt-
acetylation of neo-N-termini [10]. Monomeric NAA10
has also been described both as a lysine acetyltransferase
(KAT) [11–13] and to excerpt functions by stably interact-
ing with other proteins [14–16], although some of these
reports remain somewhat controversial. An early finding
that NAA10 is acting as a negative regulator of the tran-
scription factor HIF1α through lysine acetylation [41] was
for instance contradicted by several reports in the follow-
ing years [42–44] and more recently Magin and colleagues
showed that purified NAA10 exhibits undetectable KAT
activity in their assays [45]. In depth studies of the
NAA10-S37P causing Ogden syndrome revealed that
NAA10 had a reduced capability to form a functional
NatA complex, that it had a reduced monomeric NAT
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activity, and proteomic studies of primary cell lines re-
vealed a reduced level of Nt-acetylation of NatA substrates
mainly [23, 24]. It is likely that loss of NatA function is
more crucial than loss of monomeric NAA10 function
due to the thousands of cellular NatA substrates. Our data
suggest that the altered structure and reduced stability of
NAA10-V111G mainly affect monomeric NAA10 func-
tion, and further that this may be a common feature for
several previously described cases of pathogenic NAA10
variants. Defining the exact disease mechanism in cases
like Ogden syndrome and other NAA10 related disorders
is challenging, and it is not unlikely that it has a pleio-
tropic nature involving multiple substrates and signaling
pathways. More studies are thus needed in order to under-
stand whether NAA10 p.(V111G) (and other pathogenic
NAA10 variants) are causing disease due to loss of N-ter-
minal acetylation, loss of K-acetylation, loss of N-acetyl-
transferase independent functions or through dominant
negative effects.
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